Publication Cover
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 33, 2020 - Issue 4
119
Views
3
CrossRef citations to date
0
Altmetric
Review Articles

Hidradenitis suppurativa for the nondermatology clinician

, BS, , BS, , , MDORCID Icon & , MDORCID Icon
Pages 586-591 | Received 08 Jun 2020, Accepted 02 Jul 2020, Published online: 27 Jul 2020

  • Alikhan A , Sayed C , Alavi A , et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian hidradenitis suppurativa foundations: Part I: diagnosis, evaluation, and the use of complementary and procedural management. J Am Acad Dermatol . 2019;81(1):76–90. doi:10.1016/j.jaad.2019.02.067.
  • Vinkel C , Thomsen SF. Hidradenitis suppurativa: causes, features, and current treatments. J Clin Aesthet Dermatol . 2018;11(10):17–23.
  • Napolitano M , Megna M , Timoshchuk EA , et al. Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment. Clin Cosmet Investig Dermatol . 2017;10:105–115. doi:10.2147/CCID.S111019.
  • Zouboulis CC , Desai N , Emtestam L , et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol . 2015;29(4):619–644. doi:10.1111/jdv.12966.
  • Scuderi N , Monfrecola A , Dessy LA , et al. Medical and surgical treatment of hidradenitis suppurativa: a review. Skin Appendage Disord . 2017;3(2):95–110. doi:10.1159/000462979.
  • Ingram JR , Collier F , Brown D , et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol . 2019;180(5):1009–1017. doi:10.1111/bjd.17537.
  • Zouboulis CC , Tzellos T , Kyrgidis A , et al ; European Hidradenitis Suppurativa Foundation Investigator Group . Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol . 2017;177(5):1401–1409. doi:10.1111/bjd.15748.
  • Sartorius K , Emtestam L , Jemec GB , et al. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol . 2009;161(4):831–839. doi:10.1111/j.1365-2133.2009.09198.x.
  • Kimball AB , Sobell JM , Zouboulis CC , et al. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. J Eur Acad Dermatol Venereol . 2016;30(6):989–994. doi:10.1111/jdv.13216.
  • Dauden E , Lazaro P , Aguilar MD , et al. Recommendations for the management of comorbidity in hidradenitis suppurativa. J Eur Acad Dermatol Venereol . 2018;32(1):129–144. doi:10.1111/jdv.14517.
  • Jemec GB , Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol . 1998;39(6):971–974. doi:10.1016/s0190-9622(98)70272-5.
  • Clemmensen OJ. Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol . 1983;22(5):325–328. doi:10.1111/j.1365-4362.1983.tb02150.x.
  • Danesh MJ , Kimball AB. Pyrithione zinc as a general management strategy for hidradenitis suppurativa. J Am Acad Dermatol . 2015;73(5):e175doi:10.1016/j.jaad.2015.07.026.
  • Boer J , Jemec GB. Resorcinol peels as a possible self-treatment of painful nodules in hidradenitis suppurativa. Clin Exp Dermatol . 2010;35(1):36–40. doi:10.1111/j.1365-2230.2009.03377.
  • Mahmoud BH , Tierney E , Hexsel CL , et al. Prospective controlled clinical and histopathologic study of hidradenitis suppurativa treated with the longpulsed neodymium:yttrium-aluminium-garnet laser. J Am Acad Dermatol . 2010;62(4):637–645. doi:10.1016/j.jaad.2009.07.048.
  • Riis PT , Boer J , Prens EP , et al. Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): a case series. J Am Acad Dermatol . 2016;75(6):1151–1155. doi:10.1016/j.jaad.2016.06.049.
  • Fischer AH , Haskin A , Okoye GA. Patterns of antimicrobial resistance in lesions of hidradenitis suppurativa. J Am Acad Dermatol . 2017;76(2):309–313.e302. doi:10.1016/j.jaad.2016.08.001.
  • Alavi A , Kirsner RS. Local wound care and topical management of hidradenitis suppurativa. J Am Acad Dermatol . 2015;73(5 Suppl 1):S55–S61. doi:10.1016/j.jaad.2015.07.048.
  • Alikhan A , Sayed C , Alavi A , et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: topical, intralesional, and systemic medical management. J Am Acad Dermatol . 2019;81(1):91–101. doi:10.1016/j.jaad.2019.02.068.
  • Jemec GBE , Revuz J , Leyden J. Hidradenitis Suppurativa . Berlin, Germany: Springer; 2006:138–140.
  • Firooz A , Tehranchi-Nia Z , Ahmed AR. Benefits and risks of intralesional corticosteroid injection in the treatment of dermatological diseases. Clin Exp Dermatol . 1995;20(5):363–370. doi:10.1111/j.1365-2230.1995.tb01351.x.
  • Vural S , Gündoğdu M , Akay BN , et al. Hidradenitis suppurativa: clinical characteristics and determinants of treatment efficacy. Dermatol Ther . 2019;32(5):e13003. doi:10.1111/dth.13003.
  • van der Zee HH , Boer J , Prens EP , et al. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology (Basel) . 2009;219(2):143–147. doi:10.1159/000228337.
  • Gener G , Canoui-Poitrine F , Revuz JE , et al. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatology . 2009;219(2):148–154. doi:10.1159/000228334.
  • Smieja M. Current indications for the use of clindamycin: a critical review. Can J Infect Dis . 1998;9(1):22–28. doi:10.1155/1998/538090.
  • Yazdanyar S , Boer J , Ingvarsson G , et al. Dapsone therapy for hidradenitis suppurativa: a series of 24 patients. Dermatology (Basel) . 2011;222(4):342–346. doi:10.1159/000329023.
  • Join-Lambert O , Coignard H , Jais JP , et al. Efficacy of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa. Dermatology (Basel) . 2011;222(1):49–58. doi:10.1159/000321716.
  • Mortimer PS , Dawber RP , Gales MA , Moore RA. A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa. Br J Dermatol . 1986;115(3):263–268. doi:10.1111/j.1365-2133.1986.tb05740.
  • Sawers RS , Randall VA , Ebling FJ. Control of hidradenitis suppurativa in women using combined antiandrogen (cyproterone acetate) and oestrogen therapy. Br J Dermatol . 1986;115(3):269–274. doi:10.1111/j.1365-2133.1986.tb05741.
  • Lee A , Fischer G. A case series of 20 women with hidradenitis suppurativa treated with spironolactone. Australas J Dermatol . 2015;56(3):192–196. doi:10.1111/ajd.12362.
  • Verdolini R , Clayton N , Smith A , Alwash N , Mannello B. Metformin for the treatment of hidradenitis suppurativa: a little help along the way. J Eur Acad Dermatol Venereol . 2013;27(9):1101–1108. doi:10.1111/j.1468-3083.2012.04668.
  • Khandalavala BN , Do MV. Finasteride in hidradenitis suppurativa: a “male” therapy for a predominantly “female” disease. J Clin Aesthet Dermatol . 2016;9(6):44–50.
  • Randhawa HK , Hamilton J , Pope E. Finasteride for the treatment of hidradenitis suppurativa in children and adolescents. JAMA Dermatol . 2013;149(6):732–735. doi:10.1001/jamadermatol.2013.2874.
  • Joseph MA , Jayaseelan E , Ganapathi B , Stephen J. Hidradenitis suppurativa treated with finasteride. J Dermatolog Treat . 2005;16(2):75–78. doi:10.1080/09546630510031403.
  • Wiseman MC. Hidradenitis suppurativa: a review. Dermatol Ther . 2004;17(1):50–54. doi:10.1111/j.1396-0296.2004.04007.
  • Danto JL. Preliminary studies of the effect of hydrocortisone on hidradenitis suppurativa. J Invest Dermatol . 1958;31(6):299–300. doi:10.1038/jid.1958.124.
  • Camisa C , Sexton C , Friedman C. Treatment of hidradenitis suppurativa with combination hypothalamic-pituitary-ovarian and adrenal suppression. A case report. J Reprod Med . 1989;34(8):543–546.
  • Wong D , Walsh S , Alhusayen R. Low-dose systemic corticosteroid treatment for recalcitrant hidradenitis suppurativa. J Am Acad Dermatol . 2016;75(5):1059–1062. doi:10.1016/j.jaad.2016.06.001.
  • Reddy S , Orenstein LAV , Strunk A , Garg A. Incidence of long-term opioid use among opioid-naive patients with hidradenitis suppurativa in the United States. JAMA Dermatol . 2019;155(11):1284–1290. doi:10.1001/jamadermatol.2019.2610.
  • Saunte DM , Boer J , Stratigos A , et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol . 2015;173(6):1546–1549. doi:10.1111/bjd.14038.
  • Hendricks AJ , Hsiao JL , Lowes MA , et al. A comparison of international management guidelines for hidradenitis suppurativa. Dermatology (Basel) . 2019;:1–16.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.